Brain Sciences (Nov 2021)

Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease

  • Hsiu-Chuan Wu,
  • Kuo-Hsuan Chang,
  • Mu-Chun Chiang,
  • Chiung-Mei Chen

DOI
https://doi.org/10.3390/brainsci11111515
Journal volume & issue
Vol. 11, no. 11
p. 1515

Abstract

Read online

Parkinson’s disease (PD) is characterized by progressive neurodegeneration of dopaminergic neurons in the ventral midbrain. The complement-phagosome pathway is involved in the pathogenesis of PD. Here we measured levels of complement-phagocytosis molecules, including galectin-3, C3, C4, and cathepsin D, in the plasma of 56 patients with PD, and 46 normal controls (NCs). Plasma levels of galectin-3 (9.93 ± 3.94 ng/mL) were significantly higher in PD patients compared with NCs (8.39 ± 1.95 ng/mL, p = 0.012), and demonstrated a positive correlation with Hoehn and Yahr stages in PD patients (R2 = 0.218, p p = 0.002). However, the levels did not correlate with Hoehn and Yahr stages (R2 = 0.010, p = 0.469). Plasma levels of C4 and cathepsin D in PD patients were similar to those in NCs. Our results show possible altered complement-phagocytosis signals in the peripheral blood of PD patients, highlighting the potential of galectin-3 as a biomarker of PD.

Keywords